Objective: To probe into the drug therapy and prognosis of malignant arrhythmia in newborns. Methods: Clinical data of 36 newborns with malignant arrhythmia admitted into our hospital were retrospectively analyzed. The etiology was discussed

the antiarrhythmia drug therapy was compared and prognosis was analyzed. Results: Totally 36 newborns with malignant arrhythmia were treated with cardioversion drugs

24 cases were successful

7 cases improved

5 cases died

the effective rate was 86.1%. Twelve cases of tachyarrhythmia (n=29) were treated with single drug for cardioversion

9 cases were cardioverted after the second and third drug combination

21 cases were cured and 5 cases improved

and the effective rate was 89.7%. The effective rate of bradyarrhythmia (n=7) was 42.8%. Eight patients (22.2%) were prone to recurrent arrhythmia

and 5 patients (13.9%) required maintenance treatment. Conclusion: Different treatment methods are used for different neonatal arrhythmias

and appropriate antiarrhythmic drugs should be selected as early as possible for malignant arrhythmias. When ventricular fibrillation

ventricular flutter and paroxysmal ventricular tachycardia occur

antiarrhythmic drugs must be used immediately. Paroxysmal supraventricular tachycardia

atrial fibrillation and atrial flutter should be controlled with antiarrhythmic drugs as soon as possible. Premature beats in duplex

triplex

multi-source

parallel rhythm and frequent premature beats should be treated with antiarrhythmic drugs as appropriate

if necessary

in combination with two to three kinds of antiarrhythmic drugs. Timely detection and targeted treatment of malignant arrhythmia can help to reduce the mortality of critically ill newborns.